April 5, 2012
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), announced today that its recently reconstituted
Board of Directors has met and commenced a detailed review with independent advisors of the Company’s operations and
current financial situation. This review includes an assessment of Helix’s research and development prospects and its existing contractual and strategic relationships with a view to improving the Company’s performance.